Investigational Therapy Focuses on Slowing Progression in Mild and Moderate

Share this postShare on Google+Share on LinkedInShare on FacebookTweet about this on TwitterEmail this to someone

Researchers at Houston Methodist’s Nantz National Alzheimer Center are studying an investigational drug to slow brain cell deterioration in patients with mild to moderate Alzheimer’s disease.

T-817MA focuses on preventing brain cell loss and slowing disease progression, where current treatment options like Donepezil, Rivastigmine, and Memantine only treat the symptoms.  The scientists want to know whether the investigational therapy using the experimental drug can slow the disease progression in a more fundamental way.

The study is randomized, double-blind, and placebo-controlled.  Two-thirds of study participants receive the active study drug, but neither the patient nor the study personnel will know whether the patient is receiving the study drug until their participation in the study is finished.  This study is a Phase II clinical trial, as earlier studies assessing the efficacy of the drug have been tested on few research subjects.

People already diagnosed with mild to moderate Alzheimer’s may be eligible for the study if they are between the ages of fifty-five and eighty-five, have taken Donepezil treatment for at least six months, and live in the community and not a nursing home or assisted living facility.

Sources:

  1. Houston Methodist. (2014, August 20). Investigational therapy focuses on slowing progression in mild to moderate Alzheimer’s. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2014/08/140820105846.htm

By Emma Henson

The Roskamp Institute is a 501(c)3 research facility dedicated to translating the efforts of its qualified research staff into real-world results for those suffering from neurological diseases. To learn more about our programs and to get information about donating, visit www.rfdn.org.